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A B S T R A C T
We evaluate the efficacy of PEIT in patients with HCC using duplex color Doppler
US. The study included 27 HCC patients admitted to the University Hospital Centre
Zagreb, between 1993 and 1997. PEIT was performed for ablation of tumor supplying
vessels in HCCs of < 5 cm in diameter, and as a palliative measure for tumor feeding
vessel obliteration in larger tumors. The efficacy of PEIT was evaluated with duplex co-
lor Doppler US, and controlled by dynamic CT scan (16 patients) or selective angiography
of hepatic artery (11 patients). All patients had well vascularized tumors before PEIT,
and after therapy 25 of them showed absent or minimal tumor vascularization. Recana-
lization of the tumor feeding vessel was detected with Doppler US within 9 months after
therapy. Study results suggested that duplex color Doppler US should be the method of
choice in the evaluation of PEIT as well as in the follow-up of HCC patients after PEIT.
Keywords: hepatocellular carcinoma; percutaneous ethanol injection therapy; du-
plex color Doppler ultrasonography
Introduction
In all parts of the world, hepatocel-
lular carcinoma frequently coexists with
cirrhosis1. In ethnic Chinese and black
African populations, the cirrhosis is attri-
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buted mostly to chronic HBV infection,
whereas in countries with frequent alco-
hol consumption like Croatia2 it results
mostly from alcohol abuse, as well as
with chronic HCV infection, or both3.
Hepatocellular carcinoma (HCC) ran-
ks as the fifth most common cancer in the
world. The incidence of HCC varies wide-
ly according to geographic location. The
distribution of HCC also differs among et-
hnic groups within the same country.
Marked increase has been shown in the
USA over the last two decades, possibly
due to expanding pool of patients with
chronic hepatitis C. However, the inci-
dence of HCC in eastern Asia and middle
Africa is more than five times that of
North America and Europe (Table 1). From
1981 to 1985 the peak incidence of HCC
occurred in patients 80 to 84 years of age,
whereas from 1991 to 1995 the peak was
noted in persons 74 to 79 years of age.
This shift in incidence toward younger
population seen over last 20 years coinci-
des also with the prevalence of the hepa-
titis C infection, according to various aut-
hors1,2. The cancer is associated with
multiple genetic mutations in the chro-
mosomes of affected hepatocytes. These
aberrations can be detected by compara-
tive hybridization. Cellular pathways are
regulated by the p53 tumor-suppressor
gene which initiates apoptosis. p53 is aci-
vated in response to DNA damage and is
frequently mutated in HCC4,5. In more
than 90% of patients, HCC occurs in asso-
ciation with liver cirrhosis6,7. Therefore,
many cirrhotic patients currently under-
go screening procedures for an early de-
tection of HCC, such as alpha-fetopro-
tein8,9 and sonography10–12. This practice
has resulted in an increased rate of detec-
tion of small and unifocal HCC lesions6,7.
However, many patients with HCC are
not eligible for surgical resection of the li-
ver for a variety of reasons, e.g., hepatic
dysfunction due to cirrhosis, associated
with a high risk of postoperative hepatic
failure; advanced age; or extension or
multifocal nature of the tumor6,13. Thus,
for a majority of HCC patients the best
methods of treatment are those that resu-
lt in minimal damage to the uninvolved
hepatic tissue. That is why an increasing
number of HCC patients are now treated
with conservative therapies14,15.
Percutaneous ethanol injection therapy
(PEIT) has been recognized as an effective
nonsurgical treatment for HCC16,17, be-
cause it can achieve complete necrosis of
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TABLE 1
INCIDENCE OF HEPATOCELLULAR
CARCINOMA IN VARIOUS COUNTRIES AND














































* According to 1. Parkin, D. M., Muir, C. S.,
Whelan, S. L., Cancer Incidence in Five Conti-
nents, Vol. 5. IARC Publication No. 120. Lyon,
International Agency for Research on Cancer,
1997. and 2. Bosch, F. X., Ribes, J, Borras, J.,
Semin. Liver Dis., 13 (1999) 271.
the tumor with minimal damage to the
noncancerous hepatic parenchyma18. It
has proved to be a safe, effective and in-
expensive treatment option for patients
with cirrhosis and HCC19, especially for
the majority of HCCs with a diameter of
<5 cm. However, in daily routine, patients
with larger tumors are frequently encoun-
tered. In this case, Doppler ultrasonog-
raphy (US) is used to identify the tumor
supplying vessel, followed by US-guided
PEIT for tumor hypoperfusion by obliter-
ation of its feeding vessel. Diagnostic im-
aging is then important to help determine
whether complete necrosis of the treated
tumor has been achieved, or additional
treatment is needed20,21.
In addition, hepatocellular carcinoma
has a characteristic appearance on color
Doppler flow imaging22. We hypothesized
that duplex color Doppler US might be
highly useful in evaluating the effects of
PEIT on large HCC as well as for demon-
strating tumor recurrence during the fol-
low-up period, which we tried to prove in
the present study.
Patients and methods
The study included 27 HCC patients
(mean age 68, range 35–80 years) admit-
ted between 1993 and 1997 to the Inter-
ventional Gastroenterology Unit, Divi-
sion of Gastroenterology, Department of
Internal Medicine, University Hospital
Centre in Zagreb, Croatia. There were 23
(85%) men (mean age 65, range 35–80
years) and four (15%) women (mean age
72, range 70–74 years). The patients we-
re classified according to Child liver clas-
sification20, tumor size, and flow rate in
the tumor supplying vessel as measured
by Doppler US. Two (7%) patients were
classified as Child A, three (11%) as Child
B, and 22 (82%) as Child C.
B-mode US and duplex color Doppler
echography were performed on an Aloka
SSD 660 device with a 3.5 MHz convex
probe. Tumor size was assessed from the
largest tumor diameter (in centimeters)
measured by US. Focal lesions were exa-
mined by real-time B-mode color Doppler
yielding qualitative findings for well vascu-
larized regions of the tumor. The qualitati-
ve signals thus obtained were quantitati-
vely analyzed. Blood flow was calculated
from three measurements of peak systolic
flow rate that was digitally converted to
cm/s. The angle of measurement was 45
degrees and was not corrected, as in most
cases only a small section of the blood
vessel was visualized.
PEIT was performed under US guid-
ance using standard criteria and a Chiba
needle for ethanol application. The short-
est and optimal route from the skin to the
focal lesion, i.e. to the tumor feeding blood
vessel, was always used.
Therapy with percutaneous tumor
sclerozation was performed with 96% ste-
rile ethanol until a negative Doppler sig-
nal was obtained over the tumor supply-
ing blood vessel, which was achieved in
24 patients. In three patients, the proce-
dure had to be discontinued for technical
reasons at a point of substantial blood
flow reduction. The mean amount of etha-
nol applied into the liver tumor was 18
(range 6–40) ml. A mean of 3 (range 1–8)
sessions per patient with a mean of 5
(range 3–10) ml of ethanol per procedure
were performed.
Study patients were randomly (i.e. ac-
cording to availability of the method) al-
located to control examination by dyna-
mic computed tomography (CT) scan and
selective angiography of hepatic artery
before and after PEIT. Dynamic CT scan
was performed on a SomatomDRH, a third-
generation CT device. Stratified images
were obtained at 8 mm within 20–30 sec-
onds from administration of triiodide wa-
ter-soluble contrast medium as a 60–100
ml bolus.
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Angiography was performed on a Di-
gitron 2 device for digital subtraction an-
giography (DSA). Diagnostic evaluation
was done according to the following algo-
rithm: 1) abdominal angiography; 2) se-
lective imaging of celiac artery along with
visualization of the splenoportal venous
axis and intrahepatic portal arborization;
3) selective or supraselective imaging of
the common and left or right hepatic arte-
ry, depending on the tumorous lesion lo-
calization; and 4) control angiography in
14 days from the last PEIT session.
Tumor perfusion was divided into the
arterial and venous type, each of them be-
ing subdivided into the peripheral (peri-
tumoral) and intratumoral type. The cri-
teria of good, moderate and poor tumor
perfusion were established by consensus
of three radiologists who either observed
or performed all the radiologic studies de-
scribed. The categories of good, moderate
and poor tumor perfusion referred to
>50%, <50% and <10% intratumoral con-
trast medium uptake, respectively24.
Biochemical parameters (alpha-fetop-
rotein, aspartate aminotransferase, alani-
ne aminotransferase, alkaline phospha-
tase, gamma glutamyltransferase) were
determined by standard methods at the
Clinical Institute of Laboratory Diagno-
sis, Laboratory of Biochemistry, Universi-
ty Hospital Centre Zagreb.
Statistical analysis
Distribution of the numerical parame-
ter measurements is presented as median,
and 10th and 90th percentile (10%–90% of
measurements). Nonparametric Mann-
-Whitney test was used for between-group
comparison of measurements, and nonpa-
rametric Wilcoxon pair test for compari-
son between pre- and posttherapeutic
measurements. Correlation between the
parameters was determined by calculating
Pearson’s coefficient of correlation, and
correlation between the parameters and
dynamics of tumor recanalization by mul-
tiple regression analysis. Results of the re-
gression analysis are presented by regres-
sion coefficients (b) for the parameters,
their standard error (SE (b)), and coeffi-
cient of multiple correlation (R2). Distri-
bution of nominal parameters is shown in
contingency tables. Distribution of bina-
rized parameters was compared by use of
Fisher’s exact test. The level of signifi-
cance was set at p<0.05.
Results
Tumor size median in study patients
as measured by classic B-mode US was 9
cm, with 10th and 90th percentile of 2.8
and 18 cm, respectively. There was no
statistically significant difference in tu-
mor size between Child A/B and Child C
groups (p=0.617). Median flow rate in tu-
mor supplying blood vessel as measured
by color Doppler was 9.98 cm/s, with 10th
and 90th percentile of 3.76 and 44.24
cm/s, respectively. There was no statisti-
cally significant difference in flow rate
between Child A/B and Child C groups ei-
ther (p=0.950). No correlation was found
between flow rate through the tumor sup-
plying vessel and tumor size (correlation
coefficient r = –0.021; p>0.05). There was
no statistically significant difference be-
tween Child A/B and Child C groups in
the volume of ethanol applied (p=0.151),
number of sessions (p=0.318), or volume
of ethanol used per session (p=0.803).
There was no statistically significant corre-
lation of tumor size and flow rate through
tumor supplying vessel with the volume
of ethanol applied and number of sessions
performed (data not shown).
The efficacy of PEIT was assessed by
dynamic CT scan or angiography. The pa-
tients were divided into groups according
to the method used on control examina-
tion (Table 2). Dynamic CT scan and an-
giography were employed for therapeutic
success evaluation in 16 (59%) and 11
(41%) patients, respectively. The 16 pa-
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tients submitted to control examination
by dynamic CT scan included 14 Child C
and 2 Child A/B patients, whereas control
angiography was used in 8 Child C and 3
Child A/B patients. In the group of pa-
tients with posttherapeutic CT scan con-
trol, the mean number of sessions was 3
(10th and 90th percentile, 2 and 5), with
the administration of a mean of 15.5 ml
ethanol per patient (10th and 90th percen-
tile, 6 and 25 ml). The group of patients
with angiography control had a mean of 4
sessions (10th and 90th percentile, 3 and
4), with the application of a mean of 25 ml
ethanol per patient (10th and 90th percen-
tile, 13 and 25 ml); there was no statisti-
cally significant difference between the
two groups (p=0.132 and p=0.062, respec-
tively). Neither did the mean prethera-
peutic tumor size differ between the two
patient groups; it was 9.5 (10th and 90th
percentile, 13 and 15) cm and 7.1 (10th
and 90th percentile, 4 and 18) cm in the
groups controlled by CT scan and angiog-
raphy, respectively. The mean flow rate
through the tumor supplying vessel was
9.01 (10th and 90th percentile, 4.02–24.23)
cm/s in the group controlled by CT scan,
and 12.02 (10th and 90th percentile, 5.50-
–21.58) cm/s in the group controlled by
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TABLE 2.
CLINICAL, THERAPEUTIC AND BIOCHEMICAL PARAMETERS ACCORDING TO METHOD OF
THERAPEUTIC EFFICACY EVALUATION (CT SCAN OR ANGIOGRAPHY)*


















































* Data show number of patients according to groups or median and 10–90th percentile of the mea-
surements.
TABLE 3.
PROPORTION AND DISTRIBUTION OF PATIENTS ACCORDING TO TYPE OF TUMOR PERFUSION
Type of perfusion
Type of blood vessel
Total, n (%)













Fisher’s exact test = 0.057
angiography; the difference did not reach
statistical significance (p=0.374). Accord-
ingly, there was no statistically signifi-
cant difference in any of the relevant pa-
rameters between the two patient groups
(Table 2).
Patient distribution according to type
of tumor perfusion is illustrated in Table 3.
All the four (15%) patients with intra-
tumoral blood flow had a venous type of
tumor perfusion. Peripheral type of tu-
mor perfusion was observed in 23 patien-
ts, i.e. venous in 10 (37%) and arterial in
13 (48%) patients. There was no statisti-
cally significant difference according to
type of tumor perfusion (p=0.057). Resul-
ts obtained by the two methods of tumor
perfusion assessment after PEIT are
shown in Figure 1.
Before therapeutic intervention, all 27
patients had well perfused tumors accor-
ding to the dynamic CT scan or angiog-
raphy standard criteria. After PEIT, good
tumor perfusion considered as a poor the-
rapeutic response persisted in two pa-
tients only. In all the remaining 25 pa-
tients, moderate to poor tumor perfusion
considered as a good therapeutic respon-
se was recorded after PEIT. Moderate tu-
mor perfusion was observed in 10 (37%),
and poor tumor perfusion considered as
an excellent therapeutic response in 15
(56%) patients. The test of proportions
yielded a statistically significant propor-
tion change.
Relationship between tumor size and
flow rate through tumor feeding vessel
before and after PEIT, and dependence of
PEIT efficacy on tumor perfusion and
method of control evaluation are presen-
ted in Table 4.
The mean tumor size reduction of 0.4
cm, achieved in all tumors under study,
was statistically significant (p<0.001)
(Table 4). Tumor size reduction did not
depend on the type of tumor perfusion
(p=0.937), and there was no statistically
significant difference according to the
method of therapeutic success evaluation,
i.e. dynamic CT scan or angiography. The
mean overall difference in intratumoral
flow rate measured before and after PEIT
was 9.8 cm/s, with a statistically signifi-
cant posttherapeutic flow rate decrease
(p<0.001). The intratumoral flow rate
measured by Doppler showed a compara-
ble reduction irrespective of the CT- or
angiography-determined perfusion cate-
gory, method of perfusion assessment, and
type of perfusion (intratumoral or periph-
eral/peritumoral). In contrast to these pa-
rameters, arterial flow rate was statisti-
cally more significantly reduced than ve-
nous flow rate (p<0.05) (Table 4).
Upon therapy completion, recanaliza-
tion of the obliterated blood vessel or neo-
vascularization occurred. The median ti-
me to the recurrence of Doppler signal
over the site of ethanol application was 6
months after PEIT, and 9 months (10th
786
















Fig 1. Assessment of tumor perfusion (CT scan/angiography) before and after PEIT.
and 90th percentile, 0 and 9 months) in
the study population as a whole.
Results of the analysis of the factors
that may play a role in the process of vas-
cularization are presented in Table 5. A
statistically significant correlation was
found between flow rate through tumor
supplying vessel before PEIT and dynam-
ics of vascular recanalization (r = –0.386;
p=0.046). Parameter analysis showed the
supplying vessel recanalization to occur
earlier in patients with higher initial flow
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TABLE 4.
TUMOR SIZE AND FLOW RATE THROUGH TUMOR SUPPLYING VESSEL BEFORE AND AFTER PEIT,
AND DEPENDENCE OF PEIT EFFICACY ON TUMOR PERFUSION AND METHOD OF CONTROL
Tumor size (cm) Flow rate (cm/s)
Median 10–90% p Median 10–90% p
Before PEIT 9.1 3–16 9.98 4.23–24.23
After PEIT 8.7 2.7–15 0 0–8,32
Difference 0.4 0–1.1 p<0.001 9.80 4.23–21.58 p<0.001
Posttherapeutic difference according to tumor perfusion*
Moderate perfusion (n=10) 0.25 0–1.7 11.0 3.89–24.32
Poor perfusion (n=15) 0.1 0–1.1 p=0.937 8.32 5.23–21.34 p=0.437
Posttherapeutic difference according to method of control
CT scan (n=16) 0 0–2.4 8.32 4.02–20.34
Angiography (n=11) 0.3 0–1.0 p=0.805 10.11 5.51–21.58 p=0.278
Artery Doppler (n=13) – – – 15.72 8.32–24.23
Vein Doppler (n=14) – – – 7.79 4.02–10.82 p=0.002
Intratumoral Doppler (n=4) – – – 8.27 7.38–12.02
Peripheral Doppler (n=23) – – – 9.86 4.23–21.58 p=0.633
*Two patients with unchanged well perfused tumor after PEIT were not included in this analysis,
as they could not be compared to any other category.
TABLE 5.
CORRELATION OF TUMOR RECANALIZATION DYNAMICS (MEASURED IN MONTHS FROM
THE BEGINNING OF TREATMENT) WITH TUMOR PARAMETERS AND THERAPY USED
Correlation Multiple regression analysis
r p
 SE () p RHR (95% CIL)
Tumor before therapy (cm) –0.312 0.102 –0.167 0.087 0.068 0.85 (0.71–1.01)
Difference (cm) 0.074 0.612 – – 0.450 –
Flow rate (cm/s) –0.386 0.046 –0.288 0.077 0.001 0.75 (0.64–0.87)
Difference (cm/s) –0.049 0.807 0.303 0.108 0.010 1.35 (1.10–1.67)
Ethanol volume (ml) –0.157 0.434 – – 0.575 –
No. of sessions 0.109 0.588 – – 0.453 –
Model – – – – 0.003 –
rate through tumor supplying vessels.
The analysis also indicated the prethera-
peutic tumor size and flow rate through
tumor supplying blood vessel, and pre- to
posttherapeutic flow rate difference to be
highly useful in the monitoring of recana-
lization dynamics (Table 5), as they proved
to be statistically significant and mutual-
ly independent (p<0.05 for all parameters
except for pretherapeutic size, where
p<0.07). During the study, the following
routine biochemistry parameters were
determined before and immediately after
PEIT: alkaline phosphatase (AP), alanine
aminotransferase (ALT), aspartate ami-
notransferase (AST), and gamma gluta-
myltransferase (GGT). The values of the-
se parameters showed no statistically
significant changes during the procedure
(p>0.05 for all parameters).
Discussion
In clinical routine, a great number of
patients with advanced HCC of >5 cm in
diameter and poor hepatic functional re-
serve, who require optimal and most ra-
tional mode of treatment are encounte-
red. Besides the large primary tumor,
these patients often have satellite le-
sions, massive blood vessel infiltration,
and poor functional parameters accompa-
nying Child C stage liver cirrhosis. Be-
cause of their condition, these patients
are noneligible for liver transplantation
or resection, as well as for transarterial
embolization and chemoembolization due
to frequent portal vein thrombosis. The-
reapeutic choice is thus limited to syste-
mic chemotherapy, its beneficial effects
being quite unconvincing25, and PEIT26.
PEIT has been well established in the
management of small solitary HCCs,
whereas in many centers it is used with
much caution for large HCCs. The basic
concept of PEIT is to achieve tumor mass
reduction by tumor coagulation necrosis
induced by intratumoral alcohol instilla-
tion. In large tumors, this may be associa-
ted with a high risk of complications such
as abscesse or rupture into the abdominal
cavity with bleeding27,28.
PEIT is performed under standard US
guidance, because the real-time control
allows for rapid therapeutic procedure,
precise Chiba needle intralesional direc-
tion, and continuous monitoring through-
out the procedure. The latter is of para-
mount importance, since it allows for
appropriate control of the injected etha-
nol distribution and prompt identifica-
tion of possible ethanol escape into a lar-
ge blood vessel or peritoneal cavity, which
may lead to complications such as biliary
duct lesions or undesired vascular throm-
bosis in the healthy tissue adjacent to the
tumor29,30.
Standard US is limited by the fact
that the method cannot be used to follow
up the PEIT therapeutic success. The cri-
teria of standard US cannot differentiate
between complete necrosis and possible
persistence of viable tumor cells in the
treated area. Therefore, dynamic CT
scan, magnetic resonance (MR) or angiog-
raphy should be used on pre-, peri- and
posttherapeutic control, which implies
both ethical and financial problems. Wit-
hout appropriate control, however, some
untreated areals may quite easily be left
in the tumor, or an unnecessary high
amount of ethanol may be instilled into
the already completely necrotic areal, thus
exposing the patient to the risk of life-
threatening complications.
In the present study, the role of duplex
color Doppler US as a valuable adjuvant
method in the monitoring of PEIT for ma-
lignant liver carcinoma was inaugurated.
In our approach, color Doppler US is used
to identify the tumor supplying vessel, to
repeatedly inject a small amount of etha-
nol paravasally to obliterate the vessel
and to cause its thrombosis. Such an ap-
proach imitates transarterial emboliza-
tion with consequential ischemia of the
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tumor, and gradual tumor mass reduc-
tion without abrupt necrosis and large tu-
mor mass colliquation.
In 24 of 27 patients, ablation of the tu-
mor supplying vessel was achieved after
a mean of three therapeutic PEIT ses-
sions with a total of 5 ml ethanol per ses-
sion. In three patients, flow reduction was
achieved, however, the procedure had to
be discontinued for technical reasons.
Before PEIT, control examination by
dynamic CT scan was performed in 16
(59%), and by angiography in 11 (41%)
patients. According to standard criteria
of tumor perfusion, all tumors belonged
to the category of well perfused tumors,
as also indicated by color Doppler US23,31.
After PEIT, poor tumor perfusion was re-
corded in 15 (56%) and moderate perfu-
sion in 10 (37%) patients, indicating a
good therapeutic response in the group of
patients with a mean tumor size of 9 cm,
most of them classified as Child C with
poor hepatic functional reserve. In all
these patients, posttherapeutic Doppler
signal was negative. In three patients,
PEIT procedure had to be discontinued
before complete obliteration of the sup-
plying vessel had been achieved, because
of the underlying liver disease exacerba-
tion. Even then, a positive Doppler signal
was recorded over the respective areal.
Persistence of good tumor perfusion was
confirmed by comparative methods, poin-
ting to the high reliability of the nonag-
gressive US method in evaluation of liver
tumor perfusion during therapeutic pro-
cedures. There was no statistically signif-
icant difference in the amount of ethanol
and number of PEIT sessions between
patient groups classified either according
to Child or tumor size, also pointing to
high precision of the therapeutic agent
dosage under color Doppler US guidance.
An interesting distribution of the tu-
mor perfusion types as recorded by color
Doppler US was observed. So, the venous
and arterial type of tumor perfusion pre-
dominated in 14 (52%) and 13 (48%) pa-
tients, respectively. On color Doppler signal
analysis, the intratumoral and periphe-
ral types of liver tumor arterial perfusion
are usually considered32. It is of utmost
importance, as the patients with a predo-
minant venous tumor perfusion who are
not eligible for interventional procedures
such as transarterial embolization can
thus be identified. In our patients, perip-
heral tumor perfusion, either arterial
(48%) or venous (37%), prevailed, which
is consistent with literature data33.
The overall mean difference in flow ra-
te through the tumor supplying vessel of
9.8 cm/s was recorded in study patients,
indicating an excellent therapeutic res-
ponse to PEIT and statistically expressed
as a significant difference. It should be
emphasized that a significantly greater
reduction was recorded for arterial com-
pared with venous flow rate (p=0.02).
This statistical significance resulted from
the fact that arterial flow rate is by defi-
nition almost twofold venous flow rate,
and treatment was performed until the
blood flow, arterial or venous, was stop-
ped, i.e. until Doppler signal over the res-
pective vessel disappeared.
It should be emphasized, however,
that such a therapeutic approach is of
palliative nature, as most patients inclu-
ded in the study had HCCs sized >5 cm
and Child C liver cirrhosis. In these pa-
tients, the natural course of the underlying
disease leads to the feeding vessel reca-
nalization or neovascularization at an-
other site. Color Doppler has a very im-
portant role in timely detection of the
new signal over the tumor, thus enabling
the procedure to be repeated as needed.
In all our patients, Doppler signal over
the tumor was recorded again within 9
months, or at a mean of 6 months. Analy-
sis of the factors relevant for the time
needed for Doppler signal recurrence over
the tumor identified flow rate through tu-
mor supplying vessel, difference between
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pre- and posttherapeutic flow rate, and
tumor size as the variables directly deter-
mining the dynamics of repeat PEIT.
Our results showed the classic Dopp-
ler US to be the method of choice in the
follow-up of the effect of PEIT on HCC.
Sophisticated examinations such as spi-
ral CT scan or dynamic MR should be
used in strictly selected patient popula-
tion in whom tumor viability cannot be
assessed by Doppler US20,24,26,34–37. Color
Doppler US should be done just before
PEIT. Positive intratumoral Doppler sig-
nals persisting after intratumoral etha-
nol instillation confirm the presence of vi-
able tumor cells, indicating an additional
ethanol application. Doppler US is very
useful in this step of the procedure, allow-
ing for target intratumoral or peritumo-
ral application of ethanol at the site of
blood vessel thus detected. If no intratu-
moral circulation is recorded by classic
Doppler US, the examination should be
repeated with the use of a contrast signal
amplifier, whereby additional injection
therapy can be administered if necessary.
The next step to rule out false-negative
results includes the use of conventional
radiologic methods or recent methods of
spiral CT scan and dynamic MR38.
The presented protocol of the follow-
up of the therapeutic success achieved by
PEIT has a number of advantages. Fir-
stly, allowing for multiple target ethanol
injection into the viable portions of HCC,
repeat ethanol injections into the HCC
portions where the tumor has already
been destroyed are avoided, thus reduc-
ing the length of treatment and number
of interventions. Secondly, such a follow-
up allows for controlled ethanol adminis-
tration and prevents ethanol overdosage,
which may be potentially hazardous in
case of its systemic distribution31. Thirdly,
a high proportion of patients are identi-
fied who do not need expensive and inva-
sive follow-up methods such as angiog-
raphy, CT scan and MR39,40.
In conclusion, assessment of the value
of percutaneous ethanol injection therapy
for malignant tumors of the liver by dup-
lex color Doppler US was found to be a
highly reliable method. At the same time,
the method is open for the wide and rapid
implementation of the latest digital tech-
niques. Development of devices characte-
rized by improved sensitivity in the de-
tection of slow flow rates through small
intratumoral vessels, presenting a major
limitation of the classic Doppler US, is ex-
pected in the future26.
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PALIJATIVNO LIJE^ENJE HEPATOCELULARNOG KARCINOMA
POMO]U PERKUTANE INJEKCIJE ETANOLA U HRANIDBENU
ARTERIJU TUMORA POD VODSTVOM ULTRAZVUKA
S A @ E T A K
Prou~avali smo efikasnost perkutane injekcije etanola (PEIT) pod vodstvom ultra-
zvuka kod pacijanata s hepatocelularnim karcinomom. (HCC). Studija je provedena na
27 pacijenata s HCC-om primljenih u Klini~ki bolni~ki centar Zagreb, od 1993. do
1997. godine. PEIT je provo|en za ablaciju hranidbene arterije kod HCC promjera ma-
njeg od 5 cm i kao palijativna metoda kod ve}ih tumora. Efikasnost PEIT-a mjerena je s
Duplex color Dopplerom, te je kontrolirana dinami~kim CT-om (16 pacijanata) ili selek-
tivnom angiografijom hepati~ke arterije (11 pacijenata). Svi pacijenti imali su dobro
vaskularizirani tumor prije PEIT-a, a nakon terapije 25 pacijanata pokazivalo je odsu-
tnost ili minimalnu vaskularizaciju tumora. Rekanalizacija hranidbene arterije usta-
novljena je pomo}u UZV-a 9 mjeseci nakon terapije. Ovaj rad pokazuje da je Doppler
UZV metoda izbora za evaluaciju PEIT-a, kao i za pra}enje pacijenata s HCC nakon
PEIT-a.
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